In this study we show that treatment with MEK inhibitor consistently decreased PD-L1 mRNA and protein expression levels in vitro. Both thyroid cancer cell lines and tumor samples from patients with BRAFV600E-mutated tumors had higher levels of PD-L1 compared with either BRAFWT tumors or matched normal tissue. This evidence concerns the gene MAP2K7 and thyroid cancer.